Form 8-K - Current report:
SEC Accession No. 0001193125-25-060817
Filing Date
2025-03-24
Accepted
2025-03-24 06:23:28
Documents
16
Period of Report
2025-03-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.03: Bankruptcy or Receivership
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d933650d8k.htm   iXBRL 8-K 54806
2 EX-99.1 d933650dex991.htm EX-99.1 8287
3 EX-99.2 d933650dex992.htm EX-99.2 14589
  Complete submission text file 0001193125-25-060817.txt   247112

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA me-20250321.xsd EX-101.SCH 3207
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE me-20250321_def.xml EX-101.DEF 13269
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE me-20250321_lab.xml EX-101.LAB 21758
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE me-20250321_pre.xml EX-101.PRE 14023
19 EXTRACTED XBRL INSTANCE DOCUMENT d933650d8k_htm.xml XML 5194
Mailing Address 870 MARKET STREET ROOM 415 SAN FRANCISCO CA 94102
Business Address 870 MARKET STREET ROOM 415 SAN FRANCISCO CA 94102 (650) 938-6300
23andMe Holding Co. (Filer) CIK: 0001804591 (see all company filings)

EIN.: 871240344 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-39587 | Film No.: 25762163
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)